{
    "clinical_study": {
        "@rank": "146474", 
        "acronym": "SIRRT", 
        "arm_group": {
            "arm_group_label": "selinexor", 
            "arm_group_type": "Experimental", 
            "description": "selinexor orally twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday) at a dose of 60-120 mg based on BSA"
        }, 
        "brief_summary": {
            "textblock": "This is a multi-center, Phase 2, single arm, open-label study of oral selinexor monotherapy\n      in patients initially diagnosed with CLL and are now presenting with refractory and/or\n      relapsed RT after at least one but no more than two chemo-immunotherapy regimens for RT."
        }, 
        "brief_title": "Study of Selinexor (KPT-330) in Patients With Refractory and/or Relapsed Richter's Transformation (RT)", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Richter's Transformation", 
        "detailed_description": {
            "textblock": "This is a multi-center, Phase 2, single arm, open-label study of oral selinexor monotherapy\n      in patients initially diagnosed with CLL and are now presenting with refractory and/or\n      relapsed RT after at least one but no more than two chemo-immunotherapy regimens for RT."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A histologically confirmed diagnosis of DLBCL according to the World Health\n             Organization criteria for diagnosis of NHL in the setting of RT from CLL\n\n          -  One or more measurable (> 1.5 cm in longest dimension) disease sites on PET-CT scans\n\n          -  Objective documented evidence of disease progression at study entry\n\n          -  ECOG  status of \u2264 2\n\n        Exclusion Criteria:\n\n          -  Radiation, chemotherapy, or immunotherapy or any other anticancer therapy \u2264 2 weeks\n             prior to C1D1 and radio-immunotherapy 4 weeks prior to C1D1 provided the patient has\n             recovered to Grade \u2264 1 from clinically significant adverse effects\n\n          -  Less than 1 month since completion of autologous stem cell transplantation or less\n             than 3 months since completion of allogeneic stem cell transplantation\n\n          -  Major surgery within 4 weeks of C1D1\n\n          -  Impairment of GI function or GI disease that could interfere with the absorption of\n             selinexor, including obstructed GI tract and uncontrolled vomiting or diarrhea.\n\n          -  Inability or unwillingness to take supportive medications including a centrally\n             acting appetite stimulant (e.g., mirtazapine or olanzapine) and a peripherally acting\n             appetite stimulant (e.g., low dose glucocorticoids or megesterol acetate)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02138786", 
            "org_study_id": "KCP-330-010"
        }, 
        "intervention": {
            "arm_group_label": "selinexor", 
            "intervention_name": "selinexor", 
            "intervention_type": "Drug", 
            "other_name": "KPT-330"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Richter's Transformation", 
            "Richter's Syndrome", 
            "Karyopharm", 
            "selinexor", 
            "KPT-330"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Study of the Safety and Anti-tumor Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Refractory and/or Relapsed Richter's Transformation (RT)", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Overall Response Rate (ORR) (as defined by the IWG Criteria)", 
            "measure": "Overall Response Rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02138786"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Karyopharm Therapeutics, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Karyopharm Therapeutics, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}